Adenosine Receptor Modulation in Parkinson's Disease

Adenosine receptors, particularly the A2A subtype, play a pivotal role in the regulation of motor control and neuroinflammation through their interaction with dopaminergic signalling in the striatum. In Parkinson’s disease, loss of nigrostriatal dopamine neurons leads to an imbalance in excitatory and inhibitory pathways, and A2A receptor antagonism has emerged as a non-dopaminergic strategy to restore functional equilibrium. Preclinical studies have demonstrated that selective A2A blockers enhance motor performance and confer neuroprotection by attenuating microglial activation, modulating autophagy, and improving mitochondrial function. Clinically, adjunctive A2A receptor antagonists reduce OFF-time and motor fluctuations in patients treated with levodopa, offering improved quality of life without exacerbating dyskinesia. Epidemiological evidence for caffeine consumption further underscores the therapeutic potential of adenosine modulation, revealing risk reduction and symptom mitigation across diverse populations. Advances in medicinal chemistry, neuroimaging and translational models continue to refine our understanding of adenosine-dopamine crosstalk, paving the way for personalised interventions that combine dopaminergic and adenosinergic therapies.

Research from Nature Portfolio

No recent Nature Portfolio content available.

Adenosine Receptor Modulation in Parkinson's Disease publication trend

The graph below shows the total number of articles in adenosine receptor modulation in parkinson's disease across all publications each year (not limited to Nature Index journals).

Technical terms

Adenosine A2A receptor: A G protein-coupled receptor enriched in the striatum that modulates dopaminergic D2 receptor signalling and influences motor function and neuroinflammation.

Antagonist: A molecule that binds to a receptor without activating it, thereby preventing the endogenous ligand from eliciting its biological effect.

Dopaminergic neurotransmission: The process by which dopamine is synthesised, released, binds to receptors and is cleared from synapses, central to movement control.

Levodopa-induced dyskinesia: Involuntary, erratic movements arising as a complication of long-term levodopa therapy in Parkinson’s disease patients.

Nigrostriatal pathway: The neural tract linking the substantia nigra pars compacta to the dorsal striatum, whose degeneration underlies the cardinal motor symptoms of Parkinson’s disease.

References

1. A2A Adenosine Receptor Antagonists and Their Efficacy in Rat Models of Parkinson’s Disease. Cells (2025).
2. Caffeine and Parkinson’s Disease: Multiple Benefits and Emerging Mechanisms. Frontiers in Neuroscience (2020).
3. Adenosine A2A receptor antagonist istradefylline reduces daily OFF time in Parkinson's disease. Movement Disorders (2013).
4. The Effect of Caffeine on the Risk and Progression of Parkinson’s Disease: A Meta-Analysis. Nutrients (2020).
5. Chronic Caffeine Treatment Protects Against α-Synucleinopathy by Reestablishing Autophagy Activity in the Mouse Striatum. Frontiers in Neuroscience (2018).